| Assessment Status | NCPE Assessment Process complete |
| HTA ID | 22051 |
| Drug | Rimegepant |
| Brand | Vydura® |
| Indication | Rimegepant (Vydura®) for the treatment of acute migraine with or without aura and the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month. |
| Assessment Process | |
| Rapid review commissioned | 13/07/2022 |
| Rapid review completed | 12/09/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of rimegepant (Vydura®) compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 28/09/2022 |
| Pre-submission consultation with Applicant | 10/11/2022 |
| Full submission received from Applicant | 07/02/2023 |
| Preliminary review sent to Applicant | 27/03/2023 |
| NCPE assessment re-commenced | 18/04/2023 |
| Factual accuracy sent to Applicant | 03/05/2023 |
| NCPE assessment re-commenced | 10/05/2023 |
| NCPE assessment completed | 18/05/2023 |
| NCPE assessment outcome | The NCPE recommends that Rimegepant (Vydura) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments and that a managed access programme is introduced*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations. February 2025
